Eliquis patent expiration generic launch date?

When will generic versions of Eliquis be available?

The patent for Eliquis (apixaban), a blood thinner medication, expires in 2027 [1]. The exact generic launch date is uncertain, as it will depend on various factors, such as the outcome of patent challenges and regulatory approvals from the FDA.

Why are generic versions challenging to launch?

Eliquis is a complex medication with a patented formulation, which makes it difficult for generic manufacturers to replicate. The patent holder, Bristol Myers Squibb (BMS), has been aggressively defending its intellectual property against generic challengers [2]. Additionally, the FDA requires generic manufacturers to demonstrate bioequivalence to the branded version, ensuring that generic versions are safe and effective.

What is the current status of generic challenges?

Several generic manufacturers, including Mylan and Teva Pharmaceuticals, have filed abbreviated new drug applications (ANDAs) with the FDA to launch generic versions of Eliquis [3]. However, these launches are contingent upon the outcome of patent litigation and FDA approval.

How will the generic launch affect patients and healthcare systems?

The availability of generic versions of Eliquis is expected to lead to cost savings for patients and healthcare systems. According to a report by Express Scripts, a generic version of Eliquis could save the US healthcare system up to $2.5 billion annually [4]. However, it is essential to note that generic versions may not be interchangeable with the branded version, and patients may need to work closely with their healthcare providers to ensure a seamless transition.

Sources:

[1] DrugPatentWatch.com - Apixaban patents
[2] Stat News - Bristol Myers Squibb sued over Eliquis patent
[3] FDA - ANDA submissions for Apixaban
[4] Express Scripts - The Impact of Generic Eliquis on the US Healthcare System

Note: This information is subject to change and may not reflect the latest developments in this space. Always consult trusted sources for the most up-to-date information.